Brokers Set Expectations for Innate Pharma FY2026 Earnings

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Investment analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Innate Pharma in a research note issued to investors on Monday, September 21st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.53) for the year, up from their prior estimate of ($0.79). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Innate Pharma’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Innate Pharma’s FY2027 earnings at ($0.45) EPS and FY2028 earnings at ($0.08) EPS.

A number of other equities research analysts have also issued reports on the stock. BTIG Research reiterated a “buy” rating and set a $9.00 target price on shares of Innate Pharma in a report on Thursday, September 17th. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. Citigroup raised Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th. Finally, Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price objective for the company in a research report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.67.

Innate Pharma Price Performance

Innate Pharma stock opened at $1.80 on Wednesday. Innate Pharma has a 1 year low of $1.17 and a 1 year high of $2.71. The company’s 50 day simple moving average is $1.98 and its 200-day simple moving average is $1.75.

About Innate Pharma

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.